INDIRECT COMPARISON OF ADALIMUMAB AND VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE IN THE UNITED KINGDOM: COST PER RESPONDER/REMITTER ANALYSIS
Yifei Liu 1
William Reichmann 2
Song Wang 3
Dendy Macaulay 2
Martha Skup 3
Jingdong Chao 3
Yanjun Bao 3
1 University Of Missouri–kansas City, Kansas City, United States
2 Analysis Group, Inc., Boston, United States
3 Abbvie Inc., North Chicago, United States
Conference
UEG Week 2014
Citation
United European Gastroenterology Journal; 2014: 2 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at office@ueg.eu